+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dysmenorrhea Treatment Market by Treatment Type, Drug Class, Route of Administration, Distribution Channel, Application, End User - Global Forecast to 2030- Product Image
Dysmenorrhea Treatment Market by Treatment Type, Drug Class, Route of Administration, Distribution Channel, Application, End User - Global Forecast to 2030- Product Image
Sale

Dysmenorrhea Treatment Market by Treatment Type, Drug Class, Route of Administration, Distribution Channel, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5896360
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dysmenorrhea Treatment Market grew from USD 7.80 billion in 2024 to USD 8.51 billion in 2025. It is expected to continue growing at a CAGR of 9.02%, reaching USD 13.10 billion by 2030.

Unraveling the Complexities of Dysmenorrhea Treatment

Dysmenorrhea, characterized by recurrent painful menstrual cramps, affects a significant proportion of women of reproductive age, posing substantial clinical and socioeconomic burdens. Despite its prevalence, treatment approaches have historically been fragmented, often leaving patients to cycle through trial-and-error regimens. Chronic pain episodes carry implications for productivity, mental health, and quality of life, prompting a growing imperative to refine therapeutic pathways and deliver patient-centric solutions.

In recent years, the confluence of technological innovation, evolving patient expectations, and expanding care modalities has reshaped the dysmenorrhea landscape. Health systems are increasingly recognizing the interplay between pharmacological interventions and complementary strategies, while digital health platforms offer novel avenues for monitoring and adherence support. Against this backdrop, stakeholders seek a cohesive perspective that synthesizes clinical advances, policy shifts, and competitive dynamics.

This executive summary distills key insights from rigorous primary and secondary research, highlighting the transformative shifts, tariff impacts, segmentation nuances, regional variances, and corporate strategies defining the field today. By exploring these themes, decision-makers will be equipped to identify growth pockets, anticipate market pressures, and devise action plans that meet both clinical demands and commercial objectives.

Evolving Dynamics Reshaping Dysmenorrhea Care

The dysmenorrhea treatment paradigm is undergoing a rapid transformation fueled by interdisciplinary innovation and patient empowerment. Traditional reliance on nonsteroidal anti-inflammatory drugs and hormonal contraceptives is giving way to an integrated model that embraces non-pharmacological therapies, digital monitoring, and personalized care plans. As patients seek holistic relief, acupuncture protocols are being standardized, while heat therapy and structured exercise regimens gain validation through randomized studies.

Concurrently, digital health solutions are redefining care pathways. Mobile applications now facilitate symptom tracking, predictive analytics, and remote consultations, enabling clinicians to tailor interventions in real time. These platforms not only enhance adherence but also generate real-world evidence that informs product development and reimbursement negotiations.

Looking ahead, the convergence of clinical data, wearable sensors, and patient-reported outcomes promises to refine treatment algorithms further. Stakeholders who integrate pharmacological and complementary modalities within a digital framework will be best positioned to meet the evolving expectations of a population demanding efficacy, convenience, and transparency.

Navigating the 2025 US Tariff Landscape in Dysmenorrhea Care

In 2025, new tariff measures enacted by the United States government have introduced cost pressures across pharmaceutical and therapeutic device supply chains. Import duties on active pharmaceutical ingredients used in nonsteroidal anti-inflammatory drugs and hormonal formulations have increased production expenses, while levies on metal components for heat therapy devices have driven up manufacturing costs.

These tariff shifts have prompted manufacturers to reassess sourcing strategies. Some companies are negotiating long-term agreements with suppliers in Europe and Asia-Pacific to stabilize input prices, while others are accelerating near-shoring initiatives to mitigate duty burdens. In parallel, select firms are exploring alternative raw materials and reformulated compositions to optimize cost structures without compromising clinical performance.

The ripple effects extend to end users, who face either elevated out-of-pocket expenses or compressed profit margins in hospital and retail pharmacy channels. Payers and providers are demanding greater pricing transparency and value-based contracting to accommodate these cost fluctuations.

Organizations that proactively adapt to evolving trade policies-through diversified supplier networks, supply-chain resilience planning, and dynamic pricing models-will be better equipped to maintain market access and uphold patient affordability.

Deep Dive into Dysmenorrhea Market Segmentation Nuances

A comprehensive view of the dysmenorrhea treatment market reveals multiple layers of segmentation that inform strategic priorities. When dissected by treatment type, the landscape bifurcates into pharmacological and non-pharmacological options. Within the latter, modalities such as acupuncture, exercise therapy, and targeted heat applications have gained traction, underpinned by growing clinical validation. Dietary supplement subcategories-including herbal extracts, omega-3 formulations, and specific vitamin preparations-are experiencing notable uptake as patients seek natural adjuncts to conventional regimens.

Segmentation by drug class highlights the coexistence of hormonal contraceptives and nonsteroidal anti-inflammatory drugs, each addressing distinct pathophysiological mechanisms. The former offers cycle regulation benefits alongside pain control, while the latter remains a mainstay for immediate symptomatic relief. Delivery mechanisms further diversify the market, with injectable therapies providing rapid onset in acute cases, oral formulations ensuring convenience for sustained management, and topical applications delivering localized efficacy with reduced systemic exposure.

Distribution channels shape accessibility and patient engagement, spanning hospital pharmacy networks, digital storefronts, and traditional brick-and-mortar drugstores. Application-based segmentation distinguishes primary dysmenorrhea, driven by uterine contractions, from secondary forms associated with underlying gynecological conditions. End-user profiles encompass settings from home care environments and outpatient clinics to hospitals and specialty centers-among them fitness facilities offering therapeutic programs and dedicated gynecological clinics delivering integrated services. Understanding the distinct needs and growth dynamics across these segments is essential for tailoring product portfolios, optimizing channel strategies, and aligning value propositions with stakeholder expectations.

Regional Landscapes Defining Dysmenorrhea Treatment Growth

Regional markets exhibit distinctive characteristics that shape therapeutic adoption, competitive intensity, and growth potential. In the Americas, well-established healthcare infrastructure and favorable reimbursement frameworks support rapid uptake of both pharmacological treatments and complementary therapies. Telemedicine initiatives and digital health reimbursement codes have accelerated patient access to remote consultations and symptom tracking tools.

Across Europe, the Middle East, and Africa, regulatory landscapes vary widely. Western European nations feature mature nutraceutical markets and stringent approval requirements, while emerging economies in the Middle East and Africa underscore the role of government-sponsored awareness programs and public-private partnerships in expanding access. Differences in payer policies and local manufacturing capabilities influence pricing strategies and distribution models.

The Asia-Pacific region presents a robust opportunity fueled by a large population base, rising healthcare investments, and cultural receptivity to traditional remedies. Integration of herbal medicine with conventional protocols is commonplace in select markets, while digital health infrastructure developments are enhancing delivery of patient education and adherence support.

Across these geographies, collaboration between local distributors, global manufacturers, and technology providers is forging new care pathways and accelerating penetration of innovative solutions.

Competitive Landscape: Leading Innovators and Market Drivers

Market leadership is shaped by a diverse array of organizations, each leveraging unique capabilities. Major pharmaceutical corporations such as Pfizer, Bayer, and AbbVie drive growth through robust NSAID and hormonal therapy portfolios, underpinned by extensive clinical research and strategic alliances with contract manufacturers. Natural product specialists, including Naturex and NOW Foods, focus on optimizing extraction processes and clinical validation for herbal and omega-3 supplements, securing shelf space in both retail and online channels.

Device innovators are also vying for market share, with companies like Thermacare advancing wearable heat therapy solutions that integrate sensor feedback and personalized treatment algorithms. Concurrently, digital health start-ups are forging partnerships with fitness centers and gynecological clinics to embed symptom-tracking applications and telehealth services into patient care journeys.

Recent merger and acquisition activity underscores a trend toward convergence, as pharmaceutical players seek to augment their offerings with complementary therapies and digital tools. These transactions, along with targeted licensing agreements, are redefining competitive dynamics and unlocking cross-sector synergies.

Strategic Imperatives for Market Leadership in Dysmenorrhea

To secure a leadership position, industry participants must embrace a multifaceted strategy. Prioritizing R&D investment in precision medicine and targeted delivery systems will address heterogeneity in patient response and minimize adverse effects. Digital platforms that integrate real-time monitoring with personalized recommendations can elevate patient adherence and differentiate service offerings.

Supply chain resilience should be a core focus, with diversified sourcing frameworks and near-shoring initiatives mitigating exposure to trade volatility and tariff fluctuations. Parallel efforts in clinical validation of non-pharmacological supplements and device therapies will strengthen reimbursement cases and facilitate broader adoption.

Engagement with payers, policy makers, and professional societies early in the product lifecycle can expedite coverage determinations and foster supportive guidelines. Strategic alliances with telehealth networks and specialty centers will extend reach into underserved segments while enhancing brand equity.

By aligning innovation pipelines with evolving regulatory priorities and patient preferences, industry leaders can cultivate sustainable growth and deliver meaningful outcomes for the millions affected by dysmenorrhea.

Rigorous Methodology Underpinning Market Insights

This analysis integrates insights derived from structured primary research interviews with leading gynecologists, pain management specialists, regulatory experts, and commercial executives. A comprehensive secondary research phase examined peer-reviewed journals, clinical trial registries, regulatory filings, company publications, and industry white papers to establish a robust evidence base.

Quantitative data on treatment utilization, channel share, and competitive positioning were triangulated with qualitative perspectives from key opinion leaders to ensure contextual accuracy. Segmentation frameworks were validated through cross-comparison of internal datasets and independent third-party sources, while regional assessments incorporated local healthcare policy documentation and field surveys.

All findings underwent meticulous editorial review and stakeholder feedback loops to refine interpretations and eliminate discrepancies. The result is a cohesive set of insights that accurately reflect current dynamics and inform strategic decision-making.

Integrating Insights to Chart the Future of Dysmenorrhea Care

This executive summary has mapped the critical factors influencing dysmenorrhea treatment, from evolving patient expectations and tariff-induced cost pressures to nuanced segmentation patterns and regional particularities. Competitive analysis reveals a dynamic landscape where pharmaceutical majors, supplement specialists, and device innovators converge to address unmet needs.

By integrating pharmacological, non-pharmacological, and digital health modalities, stakeholders can craft holistic care models that resonate with diverse patient populations. Strategic focus on supply chain agility, clinical validation, and payer engagement will be pivotal in navigating future uncertainties and sustaining growth.

The insights presented herein lay the groundwork for informed action and continuous refinement of market strategies, ultimately advancing patient outcomes and unlocking commercial potential across the dysmenorrhea treatment ecosystem.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Non Pharmacological
      • Acupuncture Therapy
      • Dietary Supplements
        • Herbal Extracts
        • Omega 3 Supplements
        • Vitamin Supplements
      • Exercise Therapy
      • Heat Therapy
    • Pharmacological
  • Drug Class
    • Hormonal Contraceptives
    • Nsaids
  • Route Of Administration
    • Injectable
    • Oral
    • Topical
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Pharmacy
  • Application
    • Primary Dysmenorrhea
    • Secondary Dysmenorrhea
  • End User
    • Clinics
    • Home Care
    • Hospitals
    • Specialty Centers
      • Fitness Centers
      • Gynecological Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dysmenorrhea Treatment Market, by Treatment Type
8.1. Introduction
8.2. Non Pharmacological
8.2.1. Acupuncture Therapy
8.2.2. Dietary Supplements
8.2.2.1. Herbal Extracts
8.2.2.2. Omega 3 Supplements
8.2.2.3. Vitamin Supplements
8.2.3. Exercise Therapy
8.2.4. Heat Therapy
8.3. Pharmacological
9. Dysmenorrhea Treatment Market, by Drug Class
9.1. Introduction
9.2. Hormonal Contraceptives
9.3. Nsaids
10. Dysmenorrhea Treatment Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Topical
11. Dysmenorrhea Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Pharmacy
12. Dysmenorrhea Treatment Market, by Application
12.1. Introduction
12.2. Primary Dysmenorrhea
12.3. Secondary Dysmenorrhea
13. Dysmenorrhea Treatment Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Home Care
13.4. Hospitals
13.5. Specialty Centers
13.5.1. Fitness Centers
13.5.2. Gynecological Clinics
14. Americas Dysmenorrhea Treatment Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Dysmenorrhea Treatment Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Dysmenorrhea Treatment Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Bayer AG
17.3.2. Pfizer Inc.
17.3.3. Johnson & Johnson Services, Inc.
17.3.4. Novartis AG
17.3.5. AbbVie Inc.
17.3.6. Merck & Co., Inc.
17.3.7. Sanofi S.A.
17.3.8. GlaxoSmithKline plc
17.3.9. Teva Pharmaceutical Industries Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DYSMENORRHEA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. DYSMENORRHEA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. DYSMENORRHEA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DYSMENORRHEA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ACUPUNCTURE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OMEGA 3 SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HEAT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HORMONAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY FITNESS CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY GYNECOLOGICAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 62. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 63. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 115. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 116. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 117. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 118. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 124. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 126. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 127. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 142. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 144. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 145. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 151. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 152. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 153. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 154. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 187. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 189. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 190. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 205. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 207. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 208. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 214. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 216. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 217. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 241. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 243. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 244. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 250. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 251. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 252. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 253. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 254. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 268. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 270. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 271. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 277. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 279. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 280. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 305. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 306. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 307. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 308. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 312. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 314. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 315. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 316. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2030 (USD MILLION)
TABLE 317. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 318. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 320. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2030 (USD MILLION)
TABLE 323. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 324. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 325. JAPAN DYSMENORRHEA TREAT

Companies Mentioned

The companies profiled in this Dysmenorrhea Treatment market report include:
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.51 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.1 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Dysmenorrhea Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Dysmenorrhea Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Dysmenorrhea - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Dysmenorrhea - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Dysmenorrhea Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Dysmenorrhea Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 270 Pages
  • Global
From
Dysmenorrhea - Pipeline Insight, 2025 - Product Image

Dysmenorrhea - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Dysmenorrhea: Competitive Landscape - Product Image

Dysmenorrhea: Competitive Landscape

  • Report
  • 79 Pages
  • Global
From

About the Dysmenorrhea Drug Market

Dysmenorrhea Drug is a type of medication used to treat the pain associated with menstrual cramps. It is a common condition that affects many women of reproductive age. Dysmenorrhea Drug is a part of the Sexual and Reproductive Health Drugs market, which includes medications used to treat a variety of conditions related to sexual and reproductive health. These drugs are used to treat conditions such as infertility, endometriosis, and menopause. They can also be used to prevent pregnancy and to treat sexually transmitted infections. The Dysmenorrhea Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Bayer AG, Pfizer Inc., Merck & Co., Inc., and GlaxoSmithKline plc. Other companies in the market include Allergan plc, Teva Pharmaceutical Industries Ltd., and Mylan N.V. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.